en-us
  • zh-tw
  • en-us
  • zh-cn
  • Home
  • About Pharmasaga
    • Vision Development & Milestones
    • Organization
    • Awards
  • R&D
    • New Drug
    • Core Technology
    • Diabetes
    • Others
  • Investors
    • Financial Statements
    • Sharholder
    • Corporate Governance
    • Investor Conference
  • News Center
    • News
    • Investor Related
    • Company Related
  • Others
    • Join Pharmasaga
    • Contact Us
More
Menu

News

Investor Related
Company Related

  • [NEWS] 青年日報 : NSTC Leads 8 Biomedical Startups to the 2025 North America BIO International Convention
  • [NEWS] 中時新聞網 - 工商時報 : Emerging Stock Biotech Family Gains New Powerhouse; Pharmasaga Soars Over 100% on First Day of Listing
  • [NEWS] 中時新聞網 : New Force in New Drug Stocks! Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
  • [NEWS] 中時新聞網 - 工商時報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
  • [NEWS] 工商時報 : Emerging Stock Biotech Family Gains New Powerhouse; Pharmasaga Soars Over 100% on First Day of Listing
  • [NEWS] 工商時報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
  • [NEWS] 自由時報-自由財金 : New Drug to Reverse Diabetes? Pharmasaga Expected to List on Emerging Stock Market on 27th at NT$120
  • [NEWS] 自由時報 : New Drug to Reverse Diabetes? Pharmasaga Expected to List on Emerging Stock Market on 27th at NT$120
  • [NEWS] 台灣新生報 : Pharmasaga to List on Emerging Stock Market Tomorrow at NT$120 Per Share
  • [NEWS] TVBS新聞網 : Pharmasaga Develops Novel Diabetes Drug with 'Reversal Potential'; Listing on Emerging Stock Market on Nov. 27
  • [NEWS] 壹蘋果新聞網 : Targeting the Multi-Billion-Dollar Diabetes Drug Market; Pharmasaga to List on Emerging Stock Market the Day After Tomorrow with New Drug Development
  • [NEWS] 環球生技 : Pharmasaga's Innovative Drug for Type 1/2 Diabetes Plans Phase II, Creates Buzz Ahead of Emerging Stock Listing
  • [NEWS] GENE ONLONE : Pharmasaga Pre-Listing Investor Conference: Diabetes New Drug Shows Reversal Effect in Animal Models
  • [NEWS] 財訊快報 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120; New Type 2 Diabetes Drug to Announce Phase Ib Clinical Data in H1 Next Year
  • [NEWS] 發達網 : Pharmasaga to List on Emerging Stock Market on 27th; Type 2 Diabetes Phase Ib Clinical Trial Aims for Completion Next Year
  • [NEWS] 自立晚報 : Pharmasaga Lists on Emerging Stock Market; Innovative Diabetes Reversal Therapy Targets Market
  • [NEWS] anue鉅亨網 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
  • [NEWS] anue鉅亨網 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
  • [NEWS] 優分析 : Pharmasaga to List on Emerging Stock Market on November 27th at Reference Price of NT$120 Per Share
  • [NEWS] 經濟日報 : Biotech Newcomer Pharmasaga Lists on Emerging Stock Market on 27th at NT$120; Developing Diabetes Reversal New Drug PS1 to Enter International Market
  • [NEWS] 聚財網 : Biotech Newcomer Pharmasaga Lists on Emerging Stock Market on 27th at NT$120; Developing Diabetes Reversal New Drug PS1 to Enter International Market

Next → 


Sep 23

2021.9 PTS News: Diabetes May Be Curable - Academia Sinica Finds Reversal Key, Clinical Trials to Begin Early Next Year

薛宜家 林志堅 / Taipei Report ; Published:2021-09-23 12:56 Updated : 2021-09-23 14:43

Sep 23

2021.9 CNA News: Diabetes May Be Curable - Academia Sinica Discovers Potential Inhibitor

2021/9/23 12:51 (Updated 9/23 13:21)

Sep 23

2021.9 CTS News: Academia Sinica Discovers Reversal Mechanism, Diabetes is Poised to Be Curable!

A team from Academia Sinica's Agricultural Biotechnology Center has discovered a gene that, if overexpressed, leads to the failure of pancreatic beta-cells. Consequently, late-stage diabetic patients must rely solely on insulin injections to slow the progression of the disease. However, now that the mechanism of this gene is understood, they have...

Sep 23

2021.9 Exclusive Report by Liberty Times: Diabetes May Be Curable! Academia Sinica Team's New Discovery Holds Potential to Replace Insulin

The current situation where diabetes is considered incurable is set to be reversed! A team led by Dr. Wen-Ching Yang, a research fellow at the Agricultural Biotechnology Research Center of Academia Sinica, discovered through mouse experiments that Pdia4 (Protein Disulfide Isomerase) is responsible for regulating pancreatic beta-cells. By using the...

Sep 01

2021.9 Team's Drug Mechanism Research Published in Top-Tier International Journal, EMBO Molecular Medicine

Dr. Wen-Ching Yang's research team at Academia Sinica discovered that Pdia4 is mainly expressed in pancreatic beta-cells, and over-nutrition increases the expression of Pdia4 in human and mouse beta-cells. In diabetic mice, the Pdia4 gene knockout was found to alleviate diabetes and islet failure in the disease model, simultaneously lowering...

Jul 31

2021.7 Academia Sinica's Institute of Plant and Microbial Biology Develops First-in-Class Small Molecule Drug with Potential to Cure Diabetes, Licensed to Pharmasaga for Clinical Advancement

Diabetes Future Research and Application Symposium

Apr 01

2021.4 Pharmasaga Participated in Academia Sinica's Translational Research Center Demo Day

In April 2021, Pharmasaga presented the latest research results of PS-001 at the Demo Day event hosted by Academia Sinica's Center for Translational Research. The presentation received an enthusiastic response from many investors and professionals in attendance.

Oct 01

2020.10 PS1, a Novel Mechanism Diabetes Drug, Wins the Ministry of Science and Technology Future Tech Award

The Future Tech Exhibition 2020 (FUTEX 2020) was held from September 24th to September 26th, 2020, with over 600 startup teams participating. Our first-in-class diabetes drug, PS1, was highly honored receiving the prestigious Future Tech Award, and earning recognition from numerous domestic experts. We firmly believe that in the near future, PS1...

Newer posts Older posts

Images provided by Pexels
Cookies
Languages
  • 中文 (繁體)
  • American English
  • 中文(简体)
我們使用了 cookies 來確保我們網站的運作正常與安全性,並為您提供最佳的使用體驗。

Advanced settings

您可以在此自訂您的 cookie 偏好。啟用或關閉以下這些類別,並儲存您的選擇。

必要 cookies 對於網站與註冊過程的安全性和正確運作都至關重要。
功能性 cookies 會儲存並啟用您在網站上的 cookie 偏好。
效能性 cookies 能夠幫助觀察網站的表現狀況。
行銷性 cookies 能夠讓我們衡量與分析網站的成效。